@article{5da77ff2a5fb4fd58edb2f9284fabc78,
title = "Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.",
author = "Becker, \{Pamela S.\} and Hagop Kantarjian and Appelbaum, \{Frederick R.\} and Petersdorf, \{Stephen H.\} and Barry Storer and Pierce, \{Sherry A.\} and Jianqin Shan and Hendrie, \{Paul C.\} and Pagel, \{John M.\} and Andrei Shustov and Stirewalt, \{Derek L.\} and Stefan Faderl and Elizabeth Harrington and Estey, \{Elihu H.\}",
note = "Abstract 1065 Introduction: Clofarabine is active in both relapsed and newly diagnosed AML, and combinations of clofarabine with low-dose cytarabine appear superior to clofarabine alone. Because high-dose ara-C (HiDAC) is often more effective than lower doses, we combined clofarabine with HiDAC, together with granulocyte colony-stimulating factor (G-CSF) priming in patients with relapsed AML or AML that failed to respond to initial therapy (refractory).",
year = "2010",
month = nov,
day = "19",
language = "American English",
volume = "116",
journal = "Blood",
}